Clinical Care Options HIV http://localhost/RSS/HIV.aspx New treatment data and educational activities for HIV Clinicians en-us Clinical Care Options HIV http://images.clinicaloptions.com/img.asp?img=cco/CCO_hiv_RSS.gif http://clinicaloptions.com/hiv Management of Antiretroviral-Naive Patients http://www.clinicaloptions.com/HIV/Conference%20Coverage/Retroviruses%202009/Tracks/Naive/Naive.aspx Learning Module - Joel E. Gallant, MD, MPH; W. David Hardy, MD; and Kathleen E. Squires, MD, discuss the most clinically relevant new data on first-line treatment strategies for HIV-infected patients presented at the 2009 Conference on Retroviruses and Opportunistic Infections. Thu, 26 Mar 2009 12:00:00 GMT HIV Highlights From Montreal http://www.clinicaloptions.com/HIV/Conference%20Coverage/Retroviruses%202009/Virtual%20Presentation%20Programs/Highlights/Highlights.aspx CCO Expert Recap - Eric S. Daar, MD, reviews the most clinically relevant new data from the 2009 Conference on Retroviruses and Opportunistic Infections. Thu, 26 Mar 2009 00:00:00 GMT Resistance and Management of Treatment-Experienced Patients http://www.clinicaloptions.com/HIV/Conference%20Coverage/Retroviruses%202009/Tracks/Experienced/Experienced.aspx Learning Module - Eric S. Daar, MD; Joseph J. Eron, Jr., MD; and Kimberly Y. Smith, MD, MPH, discuss how the latest data presented at the 2009 Conference on Retroviruses and Opportunistic Infections may affect management of antiretroviral-experienced patients. Wed, 25 Mar 2009 12:00:00 GMT European Guidelines for Use of Antiretroviral Therapy: Recent Changes and Emerging Data http://www.clinicaloptions.com/HIV/Treatment%20Updates/European%20Guidelines/CCO%20Slideset/Slideset.aspx CCO Slideset - In this downloadable slideset, Jose Gatell, MD, reviews data which have influenced the latest European guidelines and emerging data which may impact future iterations of the guidelines. Mon, 23 Mar 2009 00:00:00 GMT HIV Tropism and the Use of CCR5 Antagonists in Clinical Practice: Answers to Frequently Asked Questions http://www.clinicaloptions.com/HIV/Treatment%20Updates/FAQ%20on%20Tropism/Module/Tropism%20FAQ%202.aspx Learning Module - Expert faculty members respond to frequently asked questions about HIV tropism, tropism testing, and the implications for clinical management of patients. Fri, 13 Mar 2009 08:43:08 GMT Selecting and Modifying First-line Antiretroviral Therapy in a Pregnant Patient With Transmitted Drug Resistance http://www.clinicaloptions.com/HIV/Treatment%20Updates/Assessing%20Activity/Modules/Case%203.aspx Learning Module - Charles B. Hicks, MD, discusses potential strategies for choosing an initial antiretroviral regimen for a pregnant woman with transmitted resistance. Thu, 12 Mar 2009 15:35:59 GMT European Guidelines for Use of Antiretroviral Therapy: Recent Changes and Emerging Data http://www.clinicaloptions.com/HIV/Treatment%20Updates/European%20Guidelines/Module/European%20Guidelines.aspx Learning Module - José Gatell, MD, and Anton L. Pozniak, MD, FRCP, discuss the latest European guidelines on initial antiretroviral therapy and review new data that help define the efficacy of initial regimens. Mon, 09 Mar 2009 00:00:00 GMT Pooled Week 48 MOTIVATE-1 and-2 Data: Better Efficacy, Similar Safety of Maraviroc vs Placebo in Treatment-Experienced Patients With CCR5-Using HIV-1 http://www.clinicaloptions.com/HIV/Journal%20Options/Articles/Gulick_%20Fatkenheuer_NEJM_2008a/Slideset.aspx CCO Slideset - In treatment-experienced patients infected with CCR5-using HIV-1, maraviroc plus OBR provided greater virologic, immunologic efficacy at Week 48 vs OBR alone. Mon, 02 Mar 2009 14:08:30 GMT Pooled Week 48 MOTIVATE-1 and-2 Data: Better Efficacy, Similar Safety of Maraviroc vs Placebo in Treatment-Experienced Patients With CCR5-Using HIV-1 http://www.clinicaloptions.com/HIV/Journal%20Options/Articles/Gulick_%20Fatkenheuer_NEJM_2008b/Slideset.aspx CCO Slideset - In treatment-experienced patients infected with CCR5-using HIV-1, maraviroc plus OBR provided greater virologic, immunologic efficacy at Week 48 vs OBR alone. Mon, 02 Mar 2009 14:08:30 GMT HIV Highlights From Montreal http://www.clinicaloptions.com/HIV/Conference%20Coverage/Retroviruses%202009/Virtual%20Presentation%20Programs/Highlights/Highlights%20Slides.aspx CCO Slideset - Analysis of the EuroSIDA cohort finds an 80% increase in risk of new AIDS events or death in patients with triple-class resistance and 55% elevated risk associated with double-class resistance. Fri, 27 Feb 2009 00:00:00 GMT Nearly One Half of HIV-Infected Women Wish and Intend to Have Children, but MTCT Knowledge Often Inaccurate http://www.clinicaloptions.com/HIV/Conference%20Coverage/Mexico%20City%202008/Tracks/Women/Capsules/MOAD0206.aspx Capsule Summary - Cross-sectional survey finds that 48.5% of HIV-infected women want to have children, although perceptions regarding MTCT often exaggerated Fri, 27 Feb 2009 00:00:00 GMT Review of Major Donor-Supported Antiretroviral Treatment Programs Notes Wide Variability in Outcome Indicators http://www.clinicaloptions.com/HIV/Conference%20Coverage/Mexico%20City%202008/Tracks/Resource/Capsules/MOAB0206.aspx Capsule Summary - Lack of standardization among indicators used hinders long-term goal setting and measurement of program success Fri, 27 Feb 2009 00:00:00 GMT Low CD4+ Cell Count a Risk Factor for Subclinical Atherosclerosis in HIV-Infected Individuals http://www.clinicaloptions.com/HIV/Journal%20Options/Articles/Kaplan_AIDS_2008/Slideset.aspx CCO Slideset - Cross-sectional analysis of patients in the WIHS and MACS cohorts suggest that a low CD4+ cell count, but not HAART, is associated with subclinical carotid artery atherosclerosis. Thu, 26 Feb 2009 00:00:00 GMT BENCHMRK-1 and -2: Raltegravir Well Tolerated and Associated With Significantly Higher Virologic Response vs Placebo Through Week 48 Among Patients With Multidrug Resistant HIV-1 http://www.clinicaloptions.com/HIV/Journal%20Options/Articles/Steigbigel_Cooper_NEJM_2008a/Slideset.aspx CCO Slideset - Virologic and immunologic response rates at Week 48 were observed to be higher with raltegravir vs placebo overall and across patient subgroups. Thu, 26 Feb 2009 00:00:00 GMT BENCHMRK-1 and -2: Raltegravir Well Tolerated and Associated With Significantly Higher Virologic Response vs Placebo Through Week 48 Among Patients With Multidrug Resistant HIV-1 http://www.clinicaloptions.com/HIV/Journal%20Options/Articles/Steigbigel_Cooper_NEJM_2008b/Slideset.aspx CCO Slideset - Virologic and immunologic response rates at Week 48 were observed to be higher with raltegravir vs placebo overall and across patient subgroups. Thu, 26 Feb 2009 00:00:00 GMT Evolving Options for First-line PI-Based Antiretroviral Regimens http://www.clinicaloptions.com/HIV/Treatment%20Updates/First-Line%20PI/Interactive%20Virtual%20Presentation/Presentation.aspx CCO Virtual Presentation - Watch, listen, and make treatment decisions as Douglas Ward, MD, leads you through this interactive presentation reviewing recent clinical trial data on the similarities and differences among PI-based antiretroviral regimens and the relevance of those data for individualizing first-line PI-based HIV treatment. Wed, 25 Feb 2009 12:00:00 GMT Regimen Modification Delay in Patients Failing First-line NNRTI-Based HAART Associated With Increased Risk of Disease Progression http://www.clinicaloptions.com/HIV/Journal%20Options/Articles/Petersen_AIDS_2008/Capsule.aspx Capsule Summary - NNRTI-based regimens were found to be less forgiving than PI-based regimens regarding risk of immunologic failure and mortality in patients experiencing virologic failure. Wed, 25 Feb 2009 09:26:11 GMT SMART: Current Abacavir Use Associated With Increased Risk for Cardiovascular Events, Consistent With D:A:D Findings http://www.clinicaloptions.com/HIV/Journal%20Options/Articles/Lundgren_AIDS_2008/Slideset.aspx CCO Slideset - Current use of abacavir associated with increased risk for cardiovascular disease and increased levels of select inflammatory biomarkers, although didanosine not associated with increased cardiovascular risk. Wed, 25 Feb 2009 00:00:00 GMT SMART: Current Abacavir Use Associated With Increased Risk for Cardiovascular Events, Consistent With D:A:D Findings http://www.clinicaloptions.com/HIV/Journal%20Options/Articles/Lundgren_AIDS_2008/Capsule.aspx Capsule Summary - Current use of abacavir associated with increased risk for cardiovascular disease and increased levels of select inflammatory biomarkers, although didanosine not associated with increased cardiovascular risk. Wed, 25 Feb 2009 00:00:00 GMT Low CD4+ Cell Count a Risk Factor for Subclinical Atherosclerosis in HIV-Infected Individuals http://www.clinicaloptions.com/HIV/Journal%20Options/Articles/Kaplan_AIDS_2008/Capsule.aspx Capsule Summary - Cross-sectional analysis of patients in the WIHS and MACS cohorts suggest that a low CD4+ cell count, but not HAART, is associated with subclinical carotid artery atherosclerosis. Wed, 25 Feb 2009 00:00:00 GMT